Labopharm Inc

DDS-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about DDS-T

Signal
Opinion
Expert
HOLD
HOLD
January 8, 2009
Broke through the 200-day moving average at about $1.50. Looks like the momentum may start to peter out but there is some pretty good support around $1.40. If her broke that, you should Sell.
Show full opinionHide full opinion
Labopharm Inc (DDS-T)
January 8, 2009
Broke through the 200-day moving average at about $1.50. Looks like the momentum may start to peter out but there is some pretty good support around $1.40. If her broke that, you should Sell.
DON'T BUY
DON'T BUY
December 14, 2007
Has disappointed everyone for a long time. Didn't get approval on their product. Stock has been decimated. Thinks the worst is over, but it will be a long recovery. He was actually Short the stock for a while. If you own, Hold and see what they do, but don't be a buyer.
Show full opinionHide full opinion
Labopharm Inc (DDS-T)
December 14, 2007
Has disappointed everyone for a long time. Didn't get approval on their product. Stock has been decimated. Thinks the worst is over, but it will be a long recovery. He was actually Short the stock for a while. If you own, Hold and see what they do, but don't be a buyer.
SELL
SELL
November 15, 2007
Has been a major disappointment. Guided that approvals would be fairly easy to receive, which didn't happen. Trials have been okay, not all that inclusive, so there is a lot of uncertainty.
Show full opinionHide full opinion
Labopharm Inc (DDS-T)
November 15, 2007
Has been a major disappointment. Guided that approvals would be fairly easy to receive, which didn't happen. Trials have been okay, not all that inclusive, so there is a lot of uncertainty.
BUY
BUY
November 6, 2006
Has been doing fairly well recently because they had their European and Canadian approval for their painkiller. Once they get the US of the way, it should be back over the $7 mark.
Show full opinionHide full opinion
Labopharm Inc (DDS-T)
November 6, 2006
Has been doing fairly well recently because they had their European and Canadian approval for their painkiller. Once they get the US of the way, it should be back over the $7 mark.
BUY
BUY
October 2, 2006
It is a small stock. Believes it will be a winner.
Show full opinionHide full opinion
Labopharm Inc (DDS-T)
October 2, 2006
It is a small stock. Believes it will be a winner.
WATCH
WATCH
August 23, 2005
Entering into a licensing/distribution agreement with Purdue Pharma in the US. Did a disatrous financing last year and the stock sold off. This deal was a rabbit pulled out of a hat. The stock will probably flatline for a bit after this deal. Best to see quarter after quarter how revenues kick in.
Show full opinionHide full opinion
Labopharm Inc (DDS-T)
August 23, 2005
Entering into a licensing/distribution agreement with Purdue Pharma in the US. Did a disatrous financing last year and the stock sold off. This deal was a rabbit pulled out of a hat. The stock will probably flatline for a bit after this deal. Best to see quarter after quarter how revenues kick in.
DON'T BUY
DON'T BUY
January 17, 2005
Received approval in France for its drug tramadol. Has stubbed its toes many times with investors. Large outstanding stock holding (40 Million?) could come out and flood the market.
Show full opinionHide full opinion
Labopharm Inc (DDS-T)
January 17, 2005
Received approval in France for its drug tramadol. Has stubbed its toes many times with investors. Large outstanding stock holding (40 Million?) could come out and flood the market.
DON'T BUY
DON'T BUY
January 17, 2005
Drug companies in general scare value investors. Drugs they produce might injure or kill people. Also there's a history of companies suing each other because of infringement on property rights which can tie up a small company like this. Although they got French approval, FDA could be a whole different matter.
Show full opinionHide full opinion
Labopharm Inc (DDS-T)
January 17, 2005
Drug companies in general scare value investors. Drugs they produce might injure or kill people. Also there's a history of companies suing each other because of infringement on property rights which can tie up a small company like this. Although they got French approval, FDA could be a whole different matter.
WATCH
WATCH
August 26, 2004
Management is at its risk. If they start in Europe, the stock will improve. Therefore, be cautious.
Show full opinionHide full opinion
Labopharm Inc (DDS-T)
August 26, 2004
Management is at its risk. If they start in Europe, the stock will improve. Therefore, be cautious.
DON'T BUY
DON'T BUY
May 17, 2004
Did an issue and it was a disaster. Hasn't even come close to where the issue was priced at. Behind schedule as compared to their competitors.
Show full opinionHide full opinion
Did an issue and it was a disaster. Hasn't even come close to where the issue was priced at. Behind schedule as compared to their competitors.
DON'T BUY
DON'T BUY
May 29, 2003
Still suffering from a plethora of disappointments from late 2001 and 2002. Will have a challenge moving up from where it is. Prefers others.
Show full opinionHide full opinion
Still suffering from a plethora of disappointments from late 2001 and 2002. Will have a challenge moving up from where it is. Prefers others.
DON'T BUY
DON'T BUY
May 17, 2002
Volatile. Too few projects on the go. Risky.
Show full opinionHide full opinion
Volatile. Too few projects on the go. Risky.
DON'T BUY
DON'T BUY
May 2, 2002
Interesting technology. Future is unclear. Risky.
Show full opinionHide full opinion
Interesting technology. Future is unclear. Risky.
PAST TOP PICK
PAST TOP PICK
April 1, 2002
(Was a top pick on Dec 18 down 46%) Still likes. Got hit with the pull out of Aventis, but should be able to get new deals over the next 6 months. Don't buy until they do strike a deal.
Show full opinionHide full opinion
Labopharm Inc (DDS-T)
April 1, 2002
(Was a top pick on Dec 18 down 46%) Still likes. Got hit with the pull out of Aventis, but should be able to get new deals over the next 6 months. Don't buy until they do strike a deal.
DON'T BUY
DON'T BUY
March 15, 2002
Speculative and risky. In a competitive sector.
Show full opinionHide full opinion
Labopharm Inc (DDS-T)
March 15, 2002
Speculative and risky. In a competitive sector.
Showing 1 to 15 of 28 entries